Biogen 221AD302
Back to Drug Development Trials
![]()
Drug Development Trials
About the Biogen 221AD302 trial
A Phase 3 Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIBB037) in Subjects with Early Alzheimer’s Disease.
